Peter Kaiser, PhD
Research Awards Nationwide Recipient (2014-2016)
University of California, Irvine
Drugs to Reactivate Tumor-Killing Ability of p53
One of the most commonly mutated genes in cancer and one of the most difficult proteins to target therapeutically is p53. The malfunction of p53 is crucial for the origin and spread of lung cancer. We aim develop new cancer drugs targeting p53 to help patients suffering from this terrible disease. Drugs able to reactivate the tumor-killing ability of p53 will be a significant new treatment option for thousands of lung cancer patients and will also improve treatment options for patients fighting other types of cancers.